attachment
attachment
attachment
attachment
attachment
attachment

Hey. So I'm in third year, and I'll be a student, and I have a-- I'm presently studying BSc. I'm studying a lesson, communicable diseases and epidemiology. We actually have to answer questions for exam in order, like for each disease, we have to write epidemiology, clinical features, treatment, prevention, complications. So can you like give me a pro forma that I can use for all the questions? Actually, not a pro forma, but, um... Uh, can you actually give me... You can give me the performer. Uh, I will send you the performer. I will give you the performer. Just, uh, give me any disease that I want according to that performer. Okay? Okay.

I can see your proforma clearly from the images! It's a 3-page "Communicable Disease Epidemiology" quick reference for 3rd Year MBBS/PSM covering 6 sections:
  1. Epidemiology (Agent, Host, Environmental factors + Transmission + Descriptive Epi)
  2. Clinical Features (Stages + Cardinal features + Severity classification)
  3. Diagnosis (Lab investigations + WHO/IDSP case definitions)
  4. Treatment (Supportive + Specific + Isolation & Notification)
  5. Complications (System-wise, acute, long-term)
  6. Prevention & Control (Primary/Secondary/Tertiary + Outbreak control + National Programs)
Got it perfectly. Now just tell me which disease you want, and I'll fill in every section of this proforma with exam-ready content.
Which disease do you want to start with?

Polio

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have enough to write a complete, exam-ready answer. Here it is:

POLIOMYELITIS

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM


1. EPIDEMIOLOGY

Agent Factors (Epidemiological Triad)

ParameterDetails
Causative agentPoliovirus - RNA virus, Family Picornaviridae, Genus Enterovirus
Types3 serotypes: Type 1 (most common, most paralytic), Type 2 (eradicated 2015), Type 3 (eradicated 2019)
Source of infectionHuman case or carrier (no animal reservoir - anthroponosis)
ReservoirHuman only
Infective materialFaeces (primary), oropharyngeal secretions
InfectivityHighly infectious; subclinical cases are the main source of spread
PathogenicityLow (~2% develop paralysis)
AntigenicityStrong - immunity is type-specific and lifelong after infection or vaccination

Host Factors

ParameterDetails
Age groupMainly children under 5 years ("Infantile Paralysis")
SexMales slightly more susceptible to paralytic form
ImmunityType-specific; herd immunity threshold ~80-85%
Risk factorsUnvaccinated status, pregnancy, tonsillectomy (increases bulbar polio risk), strenuous exercise during prodrome, IM injections (provocation polio)

Environmental Factors

  • Season/Climate: Temperate countries - summer/autumn peak; tropical countries - year-round
  • Geography: Endemic in Afghanistan and Pakistan (wild poliovirus type 1 remains); vaccine-derived poliovirus (VDPV) outbreaks in Africa
  • Socioeconomic: Poor sanitation, overcrowding, unsafe water supply, poverty favor spread

Transmission

ParameterDetails
ModeFaecal-oral (primary); droplet/respiratory (secondary)
VehicleContaminated water, food, hands
Portal of entryGI tract (oropharynx and intestine)
Incubation period4-35 days; usually 7-14 days for paralytic disease
Period of communicabilityVirus shed in throat for ~1 week and in faeces for 3-6 weeks; most infectious in the week before and after symptom onset

Descriptive Epidemiology

  • Global burden: Peak 350,000 cases in 125 countries in 1988; reduced >99% by vaccination. Wild-type cases: 12 in 2023 (all type 1, all from Pakistan/Afghanistan). VDPV cases remain a challenge (526 cases in 2023, mainly cVDPV2)
  • Indian scenario: India certified polio-free by WHO on 27 March 2014. Last wild poliovirus case: 13 January 2011 (Howrah, West Bengal). Under Pulse Polio Programme (PPP) since 1995-96; notifiable disease under IDSP
  • Epidemic pattern: Endemic in polio-endemic countries; epidemics in under-vaccinated populations; global campaign under Global Polio Eradication Initiative (GPEI)

2. CLINICAL FEATURES

Stages of Disease

StageFeatures
Incubation period7-14 days (range 4-35 days)
Prodromal / Minor illness stageFever, malaise, headache, sore throat, vomiting, abdominal pain (2-3 days)
Preparalytic stageReturn of fever (biphasic/dromedary fever), severe myalgia, meningism, muscle tenderness, spasm
Paralytic stage (Fastigium)Flaccid paralysis - develops rapidly over 1-3 days; maximum within a few days
ConvalescenceRecovery may occur for up to 6 months; paralysis after 6 months is permanent

Cardinal / Pathognomonic Features

  • Asymmetric flaccid paralysis WITHOUT sensory loss - hallmark finding
  • Biphasic (dromedary) fever - fever, apparent recovery, then return of fever with paralysis
  • Trendelenburg gait (gluteal muscle weakness)
  • Tripod sign / Head drop sign - due to neck muscle weakness
  • Positive "Hoyne's sign" - inability to flex neck
  • Loss of superficial and deep reflexes in affected limbs

Clinical Types / Grades / Severity Classification

TypeFeaturesFrequency
Inapparent / SubclinicalNo symptoms~90-95%
Abortive poliomyelitisMinor febrile illness, no CNS involvement, recovery in 2-3 days~4-8%
Non-paralytic (Aseptic meningitis)Meningeal signs + fever, stiff neck/back; no paralysis; full recovery~1%
Paralytic poliomyelitisFlaccid paralysis; sub-types below<2%
Sub-types of Paralytic Polio:
  • Spinal type (most common) - anterior horn cell destruction; lower limb > upper limb
  • Bulbar type - cranial nerve nuclei affected; respiratory and swallowing muscles involved; MOST DANGEROUS ⭐
  • Bulbospinal type - combined; worst prognosis

3. DIAGNOSIS

Lab Investigations

InvestigationDetails
Clinical diagnosisAcute flaccid paralysis (AFP) in child <15 years with fever at onset
Routine labsCBC (leukocytosis), CSF (increased cells - lymphocytes, normal glucose, slightly raised protein)
Specific testsStool culture for poliovirus (2 samples ≥24 hrs apart, within 14 days of onset) - gold standard; throat swab culture; CSF culture; RT-PCR
Gold standardStool virus isolation (culture) - poliovirus isolated and typed
Serology4-fold rise in neutralizing antibody titres

Case Definition (WHO / IDSP)

DefinitionCriteria
Suspected case (AFP)Any child <15 years with acute flaccid paralysis, OR any person of any age with paralytic illness if polio is suspected
Probable caseAFP + compatible epidemiological and clinical picture
Confirmed caseAFP + poliovirus isolated from stool specimen
Compatible caseAFP without adequate stool specimens and residual paralysis or death
Notifiable?YES - notifiable under IDSP; any AFP case must be reported within 24 hours to CMO

4. TREATMENT

General / Supportive Care

  • Complete bed rest during acute febrile phase (strenuous activity worsens paralysis)
  • Hydration and nutrition support
  • Antipyretics and analgesics for fever and pain
  • Moist hot packs to relieve muscle spasm
  • Careful positioning to prevent deformities
  • Monitor respiratory function (especially in bulbar type - may need mechanical ventilation)

Specific Treatment

ParameterDetails
Drug of choiceNo specific antiviral treatment available
SupportiveIV immunoglobulin (in immunocompromised patients)
Respiratory supportMechanical ventilation / iron lung for bulbar/respiratory involvement ⭐
RehabilitationPhysiotherapy, orthotic devices, corrective surgery in convalescence
ContraindicatedGlucocorticoids (steroids) worsen outcome; IM injections during febrile illness (provocation polio)

Isolation & Notification

  • Isolation type: Enteric precautions (faecal-oral route)
  • Duration: Until cultures are negative (at least 6 weeks)
  • Notification: Compulsory notification to CMO within 24 hours; any AFP case is notifiable under IDSP; International Health Regulations (IHR 2005) - polio is a PHEIC-level concern

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
Immediate / AcuteRespiratory failure (bulbar polio - MOST DANGEROUS); acute myocarditis
MusculoskeletalFlaccid paralysis, muscle wasting, joint deformities (equinus foot, claw foot), limb shortening
NeurologicalBulbar involvement - dysphagia, dysarthria, facial weakness
Long-term sequelaePost-Polio Syndrome (PPS) - new onset weakness, fatigue, pain 25-40 years after original illness
PsychologicalDepression, social isolation due to disability
Complications of treatmentPressure sores from immobility; respiratory infections
⭐ Most dangerous complication: Respiratory failure in bulbar polio ⭐ Important long-term: Post-Polio Syndrome (PPS)

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Health education about vaccination importance
  • Safe water supply and proper sewage disposal
  • Food hygiene and hand-washing
  • Nutritional improvement and improvement in living standards

Primary Prevention - Specific Protection

Immunization:
FeatureOPV (Oral Polio Vaccine / Sabin)IPV (Inactivated Polio Vaccine / Salk)
TypeLive attenuatedKilled / Inactivated
RouteOral (2 drops)Intramuscular injection
ImmunityHumoral + intestinal (mucosal IgA)Humoral only (IgG)
Herd immunityYES - virus shed, spreads immunityNo shedding
RiskVAPP (Vaccine-Associated Paralytic Polio) ~1 in 2.7 millionNone
Cold chainRequires -20°CRequires 2-8°C
India's Schedule (Universal Immunization Programme):
  • IPV: 6 weeks, 14 weeks (introduced 2015)
  • bOPV (bivalent OPV - types 1 & 3): 6, 10, 14 weeks + booster at 16-24 months
  • Pulse Polio Programme: Supplementary OPV on National Immunization Days (NIDs) and Sub-NIDs
Chemoprophylaxis: OPV given to all children <5 years during outbreak
Vector control: Not applicable (no vector)
Personal protection: Hand hygiene, safe water use

Secondary Prevention - Early Diagnosis + Prompt Treatment

  • Active AFP (Acute Flaccid Paralysis) surveillance - WHO standard: ≥1 AFP case per 100,000 children <15 years/year with adequate stool specimens = good surveillance
  • Passive surveillance through IDSP
  • Contact tracing - all contacts vaccinated immediately with OPV
  • Sentinel surveillance

Tertiary Prevention - Rehabilitation

  • Physiotherapy and occupational therapy to maximize function
  • Orthotics and assistive devices (callipers, crutches)
  • Corrective surgery (tendon transfers, arthrodesis) for deformities
  • Social and vocational rehabilitation
  • Long-term follow-up for Post-Polio Syndrome

Control Measures During an Outbreak

  • Case isolation: Enteric precautions
  • Contact tracing: All household and community contacts vaccinated with OPV within 72 hours
  • Disinfection: Concurrent disinfection of faeces, urine, vomit; terminal disinfection
  • Mop-up vaccination: Door-to-door OPV in the affected area
  • Epidemiological investigation: Attack rate, identify source, spot map, AFP surveillance
  • Notification: Immediate report to CMO, State Health Dept, IDSP war room; IHR 2005 reporting if required

National Programs & WHO Goals

ProgramDetails
Pulse Polio Programme (PPP)Launched 1995-96 in India; OPV on National Immunization Days
National Polio Surveillance Project (NPSP)AFP surveillance across India with WHO support
Global Polio Eradication Initiative (GPEI)Launched 1988 by WHO, Rotary International, CDC, UNICEF
WHO targetGlobal eradication of wild poliovirus (WPV1 remains in Pakistan/Afghanistan)
India achievementPolio-free certification by WHO - 27 March 2014
SurveillanceIDSP, IHIP, AFP surveillance network

EXAM TIPS FOR POLIO

Always MentionKey Facts
Incubation period7-14 days
Period of communicabilityStool shedding 3-6 weeks
Notifiable diseaseYes - AFP reporting within 24 hours
Herd immunity threshold~80-85%
Drug of choiceNone specific; supportive only
Gold standard diagnosisStool virus isolation (culture)
Most dangerous complicationRespiratory failure (bulbar polio)
India polio-free date27 March 2014
National programPulse Polio Programme (1995-96) + GPEI (1988)
Hallmark signAsymmetric flaccid paralysis WITHOUT sensory loss

This is a complete 10-mark answer structure. Just tell me the next disease you want and I'll fill the same proforma!

Hi

Hi! Ready when you are. Just name the next disease and I'll fill in the full proforma for you! 😊

Polio

I already covered Polio in full detail in our previous session! Here's a quick recap of the full answer — just scroll up for the complete version, or I can re-paste any specific section you need.

POLIOMYELITIS - Quick Summary

SectionKey Points
AgentPoliovirus (RNA, Picornaviridae), 3 serotypes (Type 1 most paralytic)
TransmissionFaecal-oral; incubation 7-14 days
ReservoirHuman only (anthroponosis)
Clinical TypesInapparent (90-95%), Abortive, Non-paralytic, Paralytic (<2%)
Hallmark signAsymmetric flaccid paralysis WITHOUT sensory loss
Most dangerousBulbar polio → respiratory failure ⭐
Diagnosis (Gold std)Stool virus isolation (culture)
TreatmentNo specific antiviral; supportive only
VaccinesOPV (live, oral) + IPV (killed, IM)
India polio-free27 March 2014 ⭐
National ProgramPulse Polio Programme (1995-96); GPEI (1988)
Post-polio sequelaPost-Polio Syndrome (PPS) - 25-40 years later

Do you want me to go deeper into any specific section, or shall we move on to the next disease? Just name it!

Hepatitis B

Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I have comprehensive data from Goldman-Cecil Medicine, Jawetz Medical Microbiology, and Harrison's. Here is your full proforma:

HEPATITIS B

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM


1. EPIDEMIOLOGY

Agent Factors (Epidemiological Triad)

ParameterDetails
Causative agentHepatitis B Virus (HBV) - DNA virus, Family Hepadnaviridae
StructureDane particle (42 nm) = complete virion; 22-nm spherical/tubular particles = excess HBsAg
AntigensHBsAg (surface), HBcAg (core), HBeAg (e antigen - marker of active replication)
Genotypes10 genotypes (A-J); Genotype D common in India/Mediterranean; Genotype C associated with severe disease
Source of infectionInfected humans (acute cases, chronic carriers)
ReservoirHuman only (anthroponosis)
Infective materialBlood (primary), semen, vaginal secretions, saliva, breast milk, menstrual fluid. NOT faeces
InfectivityHighly infectious - up to 10¹⁰ virions/mL in blood; virus survives drying for days
PathogenicityMost acute infections self-limiting; ~5-10% adults become chronic carriers; ~90% neonates become chronic

Host Factors

ParameterDetails
Age groupAll ages; neonates and young children at highest risk of chronicity
SexMales more commonly develop chronic disease and hepatocellular carcinoma
ImmunityAnti-HBs antibody = protective; herd immunity threshold ~80-90%
High-risk groupsIV drug users, healthcare workers, dialysis patients, multiply transfused, organ transplant recipients, men who have sex with men, infants of HBsAg-positive mothers, sexual partners of carriers
SusceptibilityImmunosuppressed patients (dialysis, HIV, chemotherapy) respond poorly to vaccine

Environmental Factors

  • Season/Climate: No seasonal trend
  • Geography: Worldwide; high endemicity in sub-Saharan Africa, East Asia, SE Asia. India is intermediate endemicity (HBsAg prevalence 2-4%)
  • Socioeconomic: Overcrowding, unsafe injection practices, lack of blood screening, poor healthcare sterilization, tattooing/piercing

Transmission

ParameterDetails
ModeParenteral (blood/blood products), Sexual (horizontal), Perinatal/Vertical (mother to child), Close contact
RoutesIV drug use (shared needles), unscreened blood transfusion, unsafe injections, sexual intercourse, mother-to-newborn at delivery
Portal of entrySkin/mucous membranes (percutaneous or mucosal exposure)
NOT transmittedFaecal-oral route - NOT documented
Incubation period45-180 days (mean 60-90 days)
Period of communicabilitySeveral weeks before onset of symptoms; throughout HBsAg positivity; chronic carriers - lifelong

Descriptive Epidemiology

  • Global burden: ~350 million chronic HBV carriers worldwide; ~600,000 deaths/year from HBV-related liver disease and hepatocellular carcinoma (WHO); 2 billion people have been infected at some point
  • Indian scenario: Intermediate endemicity; prevalence of HBsAg ~3.7-4%; Hepatitis B vaccine introduced into UIP in 2002; under National Viral Hepatitis Control Programme (NVHCP) launched 2018
  • Epidemic pattern: Endemic worldwide; no seasonal epidemic pattern; notifiable disease under IDSP

2. CLINICAL FEATURES

Stages of Disease

StageFeatures
Incubation period45-180 days (mean 60-90 days)
Prodromal stageAnorexia, nausea, malaise, fever, arthralgia, rash (serum sickness-like reaction due to immune complexes)
Icteric stage (Fastigium)Jaundice (in ~1/3 adults), dark urine, pale stools, hepatomegaly, tender liver, RUQ pain
Post-icteric / ConvalescenceGradual resolution; jaundice clears; liver enzymes normalize
Outcome90-95% adults - full recovery; 5-10% - chronic infection

Cardinal / Pathognomonic Features

  • Serum sickness-like prodrome (arthralgia, urticaria, rash) - unique to Hep B, due to HBsAg-anti-HBs immune complexes
  • Jaundice with marked hepatomegaly and elevated transaminases (ALT > AST)
  • HBsAg positivity - pathognomonic marker in blood
  • Window period - HBsAg disappears but anti-HBs not yet appeared; only anti-HBc IgM positive ⭐

Clinical Types / Grades / Severity

TypeFeatures
Inapparent / SubclinicalMajority; no symptoms, seroconversion only
Acute symptomatic hepatitis BClassic icteric illness; ~1/3 adults have jaundice
Fulminant hepatitis BMassive hepatic necrosis; hepatic encephalopathy; <1% but 60-80% mortality
Chronic hepatitis BHBsAg persists >6 months; 5-10% adults, 90% neonates
Carrier stateHBsAg positive, no active liver disease

3. DIAGNOSIS

Lab Investigations

InvestigationDetails
Routine labsLFT: raised ALT/AST (ALT > AST), raised bilirubin; CBC; PT/INR (for severity); USG abdomen
HBsAgFirst marker to appear; positive from 2-6 weeks before symptoms; persistence >6 months = chronic infection
Anti-HBc IgMMarker of acute infection; present during "window period" ⭐
HBeAgMarker of active viral replication and high infectivity
HBV DNA (PCR)Quantitative viral load; gold standard for assessing replication and treatment monitoring
Anti-HBsMarker of recovery and immunity (also post-vaccination)

Serological Interpretation Table ⭐

PhaseHBsAgAnti-HBc IgMTotal Anti-HBcAnti-HBs
Incubation++/-+/--
Acute hepatitis+++-
Window period-++-
Recovery--++
Vaccination---+
Chronic carrier+-+-

Case Definition (WHO / IDSP)

DefinitionCriteria
Suspected caseClinical jaundice + epidemiological risk factors
Probable caseClinical hepatitis + raised transaminases
Confirmed caseHBsAg positive OR anti-HBc IgM positive in acute setting
Chronic caseHBsAg positive for >6 months
Notifiable?YES - notifiable under IDSP; report to CMO

4. TREATMENT

General / Supportive Care

  • Bed rest during acute phase
  • High-calorie, low-fat diet; adequate hydration
  • Avoid hepatotoxic drugs (paracetamol in excess, alcohol, rifampicin)
  • Monitor liver function tests, PT/INR, mental status
  • Glucocorticoids are CONTRAINDICATED

Specific Treatment

ParameterDetails
Acute Hep BUsually no antiviral needed; spontaneous recovery in 95%
Severe acute Hep BAntiviral indicated if coagulopathy, persistent symptoms >4 weeks, marked jaundice
Drug of choice (chronic)Tenofovir Disoproxil Fumarate (TDF) 245 mg/day OR Tenofovir Alafenamide (TAF) 25 mg/day OR Entecavir 0.5 mg/day
AlternativesPegylated Interferon alfa-2a (finite duration, immune-mediated)
Second-lineLamivudine (resistance common - avoid as first-line), Adefovir, Telbivudine
Special populationsPregnancy: TDF preferred; Paediatrics: Entecavir or TDF; HIV co-infection: TDF + Emtricitabine (both cover HBV and HIV)
Fulminant hepatitisIntensive care; consider liver transplantation

Post-exposure Prophylaxis (PEP)

  • HBIG (Hepatitis B Immune Globulin) + HBV vaccine given simultaneously at different sites within 24 hours of exposure ⭐
  • For neonate born to HBsAg-positive mother: HBIG + Hep B vaccine within 12 hours of birth

Isolation & Notification

  • Isolation type: Blood and body fluid precautions (not enteric isolation)
  • Duration: Until HBsAg negative
  • Notification: Compulsory - notify CMO under IDSP; notifiable under IHR 2005

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
Immediate / AcuteFulminant hepatic failure (most dangerous - <1% but high mortality)
Hepatic (chronic)Chronic active hepatitis → Liver cirrhosis → Hepatocellular carcinoma (HCC)
ExtrahepaticPolyarteritis nodosa (PAN), membranous glomerulonephritis, cryoglobulinaemia, aplastic anaemia
NeurologicalGuillain-Barre syndrome (rare)
CoinfectionHDV (Hepatitis D) - only infects HBsAg-positive patients; causes more severe disease ⭐
Long-term sequelaeHCC - HBV is the #1 cause of HCC worldwide; 25% of chronic carriers develop cirrhosis/HCC
Complications of treatmentRenal toxicity with TDF; lactic acidosis with nucleoside analogues; HBV flare on stopping antivirals
⭐ Most dangerous acute complication: Fulminant hepatic failure ⭐ Most important long-term complication: Hepatocellular carcinoma (HCC)

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Health education about routes of transmission and risk behaviors
  • Safe sex practices (condom use)
  • Avoid sharing needles, razors, toothbrushes
  • Safe tattooing and ear-piercing practices
  • Screening of blood donors (HBsAg, HBcAb, HBV DNA)
  • Sterilization of medical/surgical equipment

Primary Prevention - Specific Protection

Immunization (Active):
FeatureDetails
Vaccine typeRecombinant DNA subunit vaccine (HBsAg produced in yeast)
Schedule (India UIP)Birth dose (within 24 hrs) + 6, 10, 14 weeks (as Pentavalent vaccine)
RouteIntramuscular (deltoid in adults; anterolateral thigh in infants)
Efficacy90-95% in immunocompetent individuals
SeroprotectionAnti-HBs ≥10 mIU/mL = protected
Introduced in India UIP2002 (initially 10 states); universal by 2011
BoosterNot recommended for immunocompetent persons after primary series
Passive Immunization:
  • HBIG (0.06 mL/kg IM) - for post-exposure prophylaxis; given with vaccine simultaneously
Chemoprophylaxis: TDF can be given to pregnant HBsAg-positive women with high viral load (HBV DNA >200,000 IU/mL) in third trimester to prevent vertical transmission
Universal Precautions: For all healthcare workers - gloves, masks, sharp disposal

Secondary Prevention

  • Screening of pregnant women for HBsAg - all antenatal women screened under NVHCP
  • Screening of blood donors - mandatory HBsAg, HBcAb, HBV DNA testing
  • Active case finding in high-risk groups (dialysis units, HIV patients)
  • Contact tracing of HBsAg-positive index cases; vaccination of susceptible contacts
  • Surveillance under IDSP and NVHCP

Tertiary Prevention - Rehabilitation

  • Long-term antiviral therapy to prevent cirrhosis and HCC
  • Regular monitoring: 6-monthly LFT, HBV DNA, AFP + USG abdomen (for HCC screening)
  • Management of cirrhosis complications (ascites, varices, hepatic encephalopathy)
  • Liver transplantation for end-stage liver disease
  • Psychosocial support and vocational rehabilitation

Control Measures During an Outbreak

  • Case identification and notification to CMO and IDSP
  • Contact tracing - test all household and sexual contacts for HBsAg/anti-HBs; vaccinate susceptible contacts
  • Safe injection practices enforced in outbreak setting
  • Concurrent disinfection of blood-contaminated surfaces with 1% sodium hypochlorite
  • Epidemiological investigation - identify common source (blood bank, healthcare facility)

National Programs & WHO Goals

ProgramDetails
National Viral Hepatitis Control Programme (NVHCP)Launched 28 July 2018 (World Hepatitis Day) by Ministry of Health, India ⭐
Universal Immunization Programme (UIP)Hep B vaccine as part of Pentavalent vaccine since 2002
WHO targetEliminate viral hepatitis as public health threat by 2030 (SDG 3.3); 90% reduction in new infections, 65% reduction in mortality
World Hepatitis Day28 July every year ⭐
SurveillanceIDSP, IHIP, NVHCP portal

EXAM TIPS FOR HEPATITIS B

Always MentionKey Facts
Incubation period45-180 days (mean 60-90 days)
Period of communicabilityThroughout HBsAg positivity
NotifiableYes - under IDSP
Herd immunity threshold~80-90%
Drug of choice (chronic)Tenofovir (TDF/TAF) or Entecavir
Gold standard diagnosisHBsAg + HBV DNA (PCR)
Window period markerAnti-HBc IgM ⭐
Most dangerous complicationFulminant hepatic failure (acute); HCC (long-term)
Not transmitted byFaecal-oral route
National programNVHCP (2018)
World Hepatitis Day28 July
Post-exposure prophylaxisHBIG + Vaccine within 24 hours
Unique prodromeSerum sickness-like (arthralgia + rash)

Ready for the next disease! Just name it.

Diarrhoeah

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Excellent - I have comprehensive data. Here is your full proforma:

DIARRHOEAL DISEASES

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM

Note for exam: Diarrhoeal disease is a syndrome, not a single disease. In PSM exams, questions may ask about diarrhoea as a group or specifically about Cholera, Rotavirus, or Dysentery. This proforma covers the group - always specify causative agents where asked.

1. EPIDEMIOLOGY

Agent Factors (Epidemiological Triad)

ParameterDetails
Causative agentsMultiple - see below
Viruses (70-80% in children)Rotavirus (#1 cause globally in <5 years), Norovirus, Astrovirus, Adenovirus
Bacteria (10-20%)Vibrio cholerae, E. coli (ETEC, EPEC, EIEC, EHEC), Shigella spp., Salmonella spp., Campylobacter jejuni, Clostridium difficile, Staph. aureus
Protozoa (<10%)Entamoeba histolytica, Giardia lamblia, Cryptosporidium
Source of infectionInfected humans, animals (zoonotic - Salmonella, Campylobacter), environment (V. cholerae in water)
ReservoirHuman (Shigella, Cholera), Animal (Salmonella, Campylobacter), Environment (Cholera - aquatic)
Infective materialFaeces, vomitus (Norovirus), contaminated food and water
Infective doseVaries - Shigella/EHEC: as few as 10-100 organisms; V. cholerae: 10⁵-10⁸ organisms needed
PathogenicityHigh - especially in malnourished children; malnutrition and diarrhoea form a vicious cycle

Host Factors

ParameterDetails
Age groupAll ages; highest morbidity and mortality in children <5 years
SexNo significant difference
ImmunityVaries by pathogen; limited cross-protection between types
Risk factorsMalnutrition, bottle feeding (vs breastfeeding), lack of handwashing, immunocompromise (HIV), extremes of age
Protective factorsBreastfeeding (secretory IgA), Rotavirus vaccination, good nutritional status, vitamin A

Environmental Factors

  • Season/Climate: Bacterial diarrhoea peaks in summer (heat favors bacterial growth); viral diarrhoea (Rotavirus) peaks in winter/cool dry season in tropical countries
  • Geography: High burden in South Asia, Sub-Saharan Africa; India - high endemicity especially in <5 years age group
  • Socioeconomic: Unsafe water supply, open defecation, poor sanitation, overcrowding, poverty, lack of hand-washing facilities, improper food storage/handling

Transmission

ParameterDetails
ModeFaecal-oral (primary route for ALL diarrhoeal pathogens)
Routes - 5 FsFluids (water), Food, Fingers (hands), Flies, Fomites
VehicleContaminated water (cholera, typhoid), food (Salmonella, Staph.), person-to-person contact (Shigella, Rotavirus)
Portal of entryGI tract (oral ingestion)
Incubation periodVaries: Staph. aureus toxin: 1-6 hrs; Salmonella: 6-48 hrs; Shigella: 1-3 days; Rotavirus: 1-3 days; Cholera: few hours - 5 days; Giardia: 1-3 weeks
Period of communicabilityThroughout symptomatic phase; asymptomatic carriers can shed for weeks (Salmonella typhi - up to 1 year)

Descriptive Epidemiology

  • Global burden: Diarrhoea is the 8th leading cause of death overall; 3rd leading cause of death in children <5 years; responsible for >1.6 million deaths worldwide/year; ~500,000 deaths/year in children <5 years (Rosen's EM, 2021)
  • Indian scenario: India has one of the highest burdens of diarrhoeal disease; under Integrated Management of Neonatal and Childhood Illness (IMNCI) and National Oral Rehydration Therapy (ORT) Programme; Rotavirus vaccine introduced into UIP in 2016
  • Epidemic pattern: Endemic worldwide with epidemic potential (cholera); sporadic (food poisoning); seasonal peaks; cholera - pandemic (7 pandemics, currently 7th pandemic ongoing, caused by El Tor biotype)

2. CLINICAL FEATURES

Stages of Disease

StageFeatures
IncubationHours to weeks depending on pathogen
ProdromalNausea, anorexia, abdominal discomfort, borborygmi
Acute phase (Fastigium)Loose/watery/bloody stools, abdominal cramps, fever (in invasive), vomiting, tenesmus (in dysentery)
ConvalescenceStool frequency and consistency normalize; fluid and electrolyte balance restored

Classification of Diarrhoea

By Duration:
  • Acute: <14 days
  • Persistent: 14-30 days
  • Chronic: >30 days
By Pathophysiology:
TypeMechanismExample
SecretoryEnterotoxin → ↑cAMP/cGMP → ↑Cl⁻ secretion, ↓Na⁺ absorptionCholera (V. cholerae), ETEC
OsmoticPoorly absorbed solutes retain water in gut lumenViral gastroenteritis (Rotavirus), Giardia
Inflammatory / DysentericMucosal invasion → cytotoxin → inflammationShigella, EIEC, Entamoeba histolytica
Motility-relatedAltered gut motilityIBS (non-infectious)
By Clinical Type:
TypeFeaturesCommon Agents
Watery diarrhoeaLarge-volume, watery stools, NO blood; rapid dehydrationCholera, Rotavirus, ETEC
Dysentery (bloody diarrhoea)Small-volume, bloody mucoid stools, tenesmus, feverShigella, EIEC, Entamoeba histolytica, EHEC
Food poisoningShort incubation, vomiting prominent, no feverStaph. aureus, C. perfringens

Cardinal / Pathognomonic Features

  • Dehydration signs: Sunken eyes, dry mouth, reduced skin turgor, depressed fontanelle (infants), reduced urine output ⭐
  • Rice-water stools - pathognomonic of Cholera (profuse, watery, fishy/musty odour)
  • Bloody mucoid stools + tenesmus - characteristic of Shigella (Bacillary dysentery)
  • "Starvation stools" - watery green stools in malnourished children
  • Raspberry jelly stools - Entamoeba histolytica (amoebic dysentery)

WHO Dehydration Assessment ⭐

SignNo DehydrationSome DehydrationSevere Dehydration
General conditionWell, alertRestless, irritableLethargic/unconscious
EyesNormalSunkenVery sunken
ThirstNormalThirsty, drinks eagerlyDrinks poorly/cannot drink
Skin pinchGoes back quicklyGoes back slowlyGoes back very slowly (>2 sec)
ActionHome ORS (Plan A)ORS in facility (Plan B)IV fluids (Plan C)

3. DIAGNOSIS

Lab Investigations

InvestigationDetails
Clinical diagnosisHistory of loose stools + dehydration; assess duration, frequency, blood/mucus, fever
Routine labsStool examination (macroscopic + microscopic - RBCs, pus cells, parasites, cysts); CBC; serum electrolytes; BUN/creatinine (for severity)
Stool cultureGold standard for bacterial diarrhoea; identify pathogen and antibiotic sensitivity
Stool microscopyMotile trophozoites of E. histolytica = amoebic dysentery; cysts = Giardia; RBCs in dysentery
Rapid testsCholera RDT (rapid dipstick); Rotavirus ELISA/antigen test
PCRFor viral identification (Norovirus, Rotavirus)
Hanging drop preparationDarting motility of V. cholerae - confirms cholera

Case Definition (WHO / IDSP)

DefinitionCriteria
Acute Diarrhoea≥3 loose/watery stools in 24 hours
DysenteryBlood and/or mucus in stools
Cholera SuspectedAcute watery diarrhoea with/without vomiting, in patient ≥5 years, with severe dehydration
Cholera ConfirmedV. cholerae O1 or O139 isolated from stool culture
Notifiable?YES - Cholera is notifiable under IDSP and under IHR 2005 (potential PHEIC); all clusters/outbreaks must be reported to CMO within 24 hours

4. TREATMENT

General / Supportive Care - ORS is the Cornerstone ⭐

The basis of ORS works because: The sodium-glucose co-transport mechanism in the gut remains intact during secretory diarrhoea - glucose actively carries sodium (and water) across the enterocyte even when cholera toxin is acting.
WHO-ORS Composition (Low-osmolarity ORS - 2003):
ComponentAmount per litre
Sodium chloride2.6 g
Trisodium citrate2.9 g
Potassium chloride1.5 g
Glucose (anhydrous)13.5 g
Total osmolarity245 mOsm/L
Home ORS (Sugar-Salt Solution): 1 teaspoon salt + 8 teaspoons sugar in 1 litre clean water
ORS Plans:
PlanDehydrationSettingAmount
Plan ANoneHome50-100 mL ORS after each loose stool
Plan BSomeFacility75 mL/kg over 4 hours
Plan CSevereHospital IVRinger's Lactate 100 mL/kg (infants: over 3 hrs; children: over 1 hr)
Zinc supplementation: 20 mg/day for 14 days in children (10 mg/day in <6 months) ⭐ - reduces duration and severity; recommended by WHO since 2004
Continue feeding: Early re-feeding; do NOT withhold food; breastfeeding should continue

Specific Treatment

PathogenDrug of ChoiceDose/Duration
CholeraDoxycycline (adults) / Azithromycin (children/pregnant)Doxycycline 300 mg single dose; Azithromycin 1g single dose
Shigella (Bacillary dysentery)Ciprofloxacin (adults) / Azithromycin (children)Cipro 500 mg BD x 3 days
Amoebic dysenteryMetronidazole + Diloxanide furoateMetro 800 mg TDS x 5-10 days (luminal agent follows)
GiardiaMetronidazole or TinidazoleMetro 400 mg TDS x 5 days
ETEC (Traveller's diarrhoea)Usually self-limiting; Rifaximin if neededRifaximin 200 mg TDS x 3 days
C. difficileVancomycin (oral) or FidaxomicinVancomycin 125 mg QDS x 10 days
Rotavirus/viralSupportive only (ORS + Zinc)No antivirals
Antibiotics NOT routinely recommended for acute watery diarrhoea - reserve for cholera, dysentery, and specific confirmed bacterial causes

Isolation & Notification

  • Isolation type: Enteric precautions (contact precautions for C. difficile)
  • Duration: Until symptoms resolve and 2 stool cultures negative (for cholera)
  • Notification: Cholera - compulsory notification to CMO; report to State/IHR 2005; all outbreaks reported to IDSP

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
Immediate / AcuteSevere dehydration → Hypovolaemic shock → Death (most dangerous, especially <5 years)
MetabolicHyponatraemia, Hypokalaemia, Metabolic acidosis
RenalAcute kidney injury (pre-renal) from dehydration
NeurologicalFebrile seizures (Rotavirus, Shigella); Encephalopathy (Shigella - Ekiri syndrome); Haemolytic Uraemic Syndrome (HUS) from EHEC (E. coli O157:H7) ⭐
GIIntussusception (post-Rotavirus); Toxic megacolon (Shigella, C. difficile); Intestinal perforation; Rectal prolapse (Shigella in malnourished)
NutritionalMalnutrition and growth faltering (persistent/chronic diarrhoea)
Long-termPost-infectious IBS; Reactive arthritis (Reiter's syndrome - after Shigella, Salmonella, Campylobacter)
Treatment complicationsHypernatraemia from incorrect ORS preparation; antibiotic resistance
⭐ Most dangerous complication: Severe dehydration → Hypovolaemic shock ⭐ Important specific complication: HUS from EHEC (E. coli O157:H7) - microangiopathic haemolytic anaemia + thrombocytopenia + acute kidney injury

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Health education: handwashing with soap (especially before meals, after defecation) ⭐
  • Safe water supply - boiling, chlorination, filtration
  • Proper food hygiene: cook food thoroughly, refrigerate properly, avoid raw/street food
  • Sanitation: use of latrines, ODF (Open Defecation Free) campaigns - Swachh Bharat Mission
  • Breastfeeding promotion (protective IgA, no contaminated water)
  • Nutritional improvement - Vitamin A supplementation (reduces severity)

Primary Prevention - Specific Protection

Immunization:
VaccineDiseaseTypeSchedule (India UIP)
Rotavirus vaccine (RVV)Rotavirus diarrhoeaLive attenuated oral6, 10, 14 weeks (introduced in India UIP 2016) ⭐
Oral Cholera Vaccine (OCV)CholeraKilled oral (Shanchol/OrcVax)2 doses, 2 weeks apart; used in outbreak settings
Typhoid vaccineTyphoid (enteric fever)Vi polysaccharide / TCVUIP: Typhoid Conjugate Vaccine (TCV) from 9-12 months
Chemoprophylaxis: Not recommended routinely; Doxycycline for household contacts of confirmed cholera cases (in some guidelines)
Water purification: Chlorination (0.5 ppm residual chlorine), boiling, UV purification
Personal protection: Hand hygiene (5 moments of hand hygiene), safe food handling

Secondary Prevention

  • ORT Programme - early treatment with ORS at community level; ORS corners in PHCs/subcentres
  • Zinc supplementation added to ORS since 2004 (WHO/UNICEF recommendation)
  • IMNCI (Integrated Management of Neonatal and Childhood Illness) - community-level case management by ASHA/ANM
  • IDSP surveillance - alert system for cluster of diarrhoea cases
  • Rapid reporting and investigation of outbreaks
  • Stool culture surveillance to identify dominant pathogens

Tertiary Prevention - Rehabilitation

  • Nutritional rehabilitation after episode (F-75 → F-100 formula in SAM)
  • Growth monitoring and promotion
  • Long-term follow-up for persistent/chronic cases
  • Management of post-diarrhoeal malnutrition and stunting

Control Measures During an Outbreak

  • Case isolation: Enteric precautions for all cases
  • Contact tracing: Identify source (water supply, food handler, common meal)
  • Water safety: Immediate chlorination of water supply; test water samples
  • Disinfection: Concurrent (bleach on faeces/vomit) + terminal disinfection
  • Food handler screening: Stool culture of all food handlers
  • Epidemiological investigation: Attack rate, epidemic curve, spot map; identify point source vs propagated source
  • Notification: Report to CMO, IDSP war room; cholera under IHR 2005

National Programs & WHO Goals

ProgramDetails
National ORT ProgrammePromotion of ORS at all levels; ORS packets distributed through ASHA/AWW
National Zinc ProgrammeZinc co-administered with ORS since WHO 2004 recommendation
Swachh Bharat Mission (SBM)Launched 2 Oct 2014; ODF India declared 2019; critical for diarrhoea prevention ⭐
IMNCICommunity management of childhood diarrhoea by front-line health workers
Rotavirus vaccine in UIPIntroduced April 2016; phased rollout across India ⭐
Jal Jeevan MissionPiped tap water to all rural households by 2024 - major diarrhoea prevention tool
WHO targetEnd preventable child deaths; reduce under-5 mortality (SDG 3.2)
SurveillanceIDSP, IHIP, NVBDCP (for cholera), HMIS

EXAM TIPS FOR DIARRHOEAL DISEASES

Always MentionKey Facts
Incubation periodVaries by agent (Staph 1-6 hrs → Giardia 1-3 weeks)
Period of communicabilityThroughout symptomatic period
NotifiableCholera - YES (IHR 2005 PHEIC); all outbreaks under IDSP
Most common cause in childrenRotavirus (globally); Norovirus (post-vaccination era in US)
Drug of choice for CholeraDoxycycline single dose (adults)
Drug of choice for Amoebic dysenteryMetronidazole + Diloxanide furoate
Cornerstone of treatmentORS (Plan A/B/C) + Zinc ⭐
Most dangerous complicationSevere dehydration → shock
HUS caused byEHEC (E. coli O157:H7) ⭐
National programSwachh Bharat Mission (2014) + ORT Programme + Rotavirus vaccine (UIP 2016)
Rice-water stoolsCholera (pathognomonic)
Raspberry jelly stoolsAmoebic dysentery
ORS osmolarity245 mOsm/L (low osmolarity WHO formula, 2003)
Zinc dose20 mg/day x 14 days (10 mg in <6 months)

Great coverage for a PSM exam! Just name the next disease.

Cholera

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
I have comprehensive data from Harrison's and Goldman-Cecil. Here is your full proforma:

CHOLERA

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM


1. EPIDEMIOLOGY

Agent Factors (Epidemiological Triad)

ParameterDetails
Causative agentVibrio cholerae - curved Gram-negative bacillus, Family Vibriaceae
SerogroupsO1 and O139 (epidemic potential); non-O1/non-O139 cause sporadic disease only
Biotypes of O1Classic (caused pandemics 1-6; now extinct) and El Tor (7th pandemic; currently ongoing) ⭐
Serotypes of O1Inaba, Ogawa, Hikojima
O139Emerged 1992 in southeastern India; Bengal serogroup; not cross-protective with O1
Virulence factorCholera Toxin (CT) - A+B subunits; B binds GM1 ganglioside → A subunit ADP-ribosylates Gs protein → ↑cAMP → ↑Cl⁻ secretion + ↓Na⁺ absorption → massive fluid loss ⭐
Source of infectionInfected humans (cases + carriers); aquatic environment
ReservoirAquatic (estuaries, brackish water, plankton/copepods); Human gut
Infective materialFaeces (primarily), vomitus
Infective dose10³-10⁸ via water; 10²-10⁴ via food (gastric acid provides partial protection)
PathogenicityEl Tor: more asymptomatic cases than classic biotype; O blood group at highest risk of severe disease

Host Factors

ParameterDetails
Age groupChildren >2 years in endemic areas; all ages in epidemics/new areas
SexNo significant difference
Blood groupBlood group O → highest risk of severe disease ⭐; Blood group AB → least risk
ImmunityNatural infection confers immunity for 3 years; type-specific (O1 immunity does NOT protect against O139)
Susceptibility increased byAchlorhydria, H. pylori infection (hypochlorhydria), use of PPIs/antacids, malnutrition
Herd immunity threshold~60-80% (vaccine-dependent)

Environmental Factors

  • Season/Climate: Hot season peaks; associated with high temperatures, flooding, monsoon; El Niño events increase cholera via promoting plankton blooms
  • Geography: Endemic in Africa, South Asia (Ganges delta - native origin), Latin America; 7th pandemic ongoing; India - endemic in parts of Bengal, Bihar, Odisha; notifiable
  • Socioeconomic: Unsafe water, poor sanitation, open defecation, poverty, war/displacement, flooding, breakdown of health infrastructure

Transmission

ParameterDetails
ModeFaecal-oral (primarily waterborne; also foodborne)
VehicleContaminated water (#1), contaminated food (shellfish, raw seafood, rice, vegetables), hands
Portal of entryGI tract (oral ingestion)
No animal reservoirAnthroponosis (humans only for transmission; environment is a reservoir)
Person-to-personLess common (large inoculum needed); but household attack rate ~50% in endemic areas
Incubation periodFew hours to 5 days (usually 24-48 hours) ⭐
Period of communicabilityThroughout symptomatic phase (stool positive); El Tor carriers shed for weeks to months; chronic gallbladder carrier state possible

Descriptive Epidemiology

  • Global burden: True burden estimated at 1-4 million cases/year; 20,000-140,000 deaths/year (severe underreporting - only ~400,000 reported to WHO/year); major outbreaks in Haiti (2010-2022), Yemen (2016-2017), Africa currently ⭐
  • 7 Pandemics: First in 1817 (Ganges delta, India); 7th pandemic began 1961 in Indonesia (El Tor biotype); currently ongoing; O139 emerged India 1992
  • Indian scenario: Cholera endemic in several states; notifiable disease under IDSP; National Cholera Control Programme; outbreaks during floods/post-disaster
  • Epidemic pattern: Endemic with epidemic/pandemic potential; point-source outbreaks (contaminated water supply) + propagated spread; classic epidemic curve = explosive point-source

2. CLINICAL FEATURES

Stages of Disease

StageFeatures
Incubation periodFew hours to 5 days (usually 24-48 hours)
Prodromal stageUsually absent - sudden onset
Acute phase (Fastigium)Sudden painless profuse watery diarrhoea ± vomiting; NO fever; muscle cramps
ProgressionRapid dehydration → shock → death if untreated (can die within hours)
ConvalescenceFull recovery with adequate rehydration; self-limiting in 2-5 days

Cardinal / Pathognomonic Features ⭐

  • "Rice-water stools" - profuse, watery, non-bilious, gray, cloudy with mucus flecks, slightly fishy odour - PATHOGNOMONIC
  • Painless diarrhoea (no tenesmus, no blood) - due to secretory mechanism, not invasion
  • NO fever (distinguishes from dysentery)
  • "Washerwoman's hands/skin" - severe wrinkling of skin from dehydration ⭐
  • Sunken eyes, sunken fontanelle (infants), loss of skin turgor
  • Hypotension, rapid weak pulse (hypovolaemic shock)
  • "Cholera voice" (vox choleraica) - hoarse whisper from dehydration
  • Muscle cramps (hypokalaemia, hyponatraemia)
  • Stool output can exceed 250 mL/kg/24 hours in severe cases

Dehydration Grading

DegreeClinical Signs% Body Weight Loss
None/MildThirst only<5%
ModerateThirst, postural hypotension, tachycardia, decreased skin turgor, dry mucosa5-10%
SevereUnconscious/lethargic, absent pulse, sunken eyes, cannot drink, washerwoman skin>10%

Clinical Types

TypeFeatures
AsymptomaticMajority (El Tor biotype especially); subclinical infection
Cholera siccaSevere form with massive fluid sequestration in gut but minimal external diarrhoea; severe shock; often fatal before diarrhoea appears ⭐
Cholera gravisClassic severe cholera with profuse rice-water diarrhoea, rapid dehydration, shock
Mild choleraWatery diarrhoea resembling ordinary gastroenteritis; self-limiting

3. DIAGNOSIS

Lab Investigations

InvestigationDetails
Clinical diagnosisPatient ≥5 years + acute watery diarrhoea + severe dehydration in endemic/epidemic area
Routine labsElevated haematocrit (haemoconcentration), elevated BUN/creatinine, ↓bicarbonate (<15 mmol/L), elevated anion gap, low arterial pH (~7.2), normal Na⁺/K⁺/Cl⁻ initially
Stool microscopy (Hanging drop)Darting motility ("shooting star" motility) of vibrios; immobilisation by specific O1 antisera confirms diagnosis
Dark field microscopyCurved rods with characteristic motility in fresh stool
Stool culture (Gold standard)⭐ Selective media: TCBS agar (Thiosulphate Citrate Bile Salt Sucrose) - yellow colonies; or Alkaline Peptone Water (APW) enrichment broth (pH 8.6)
Rapid diagnostic test (RDT)Cholera RDT dipstick - bedside; useful in field/outbreak settings
PCRFor O1/O139 confirmation and biotyping
SerologyVibriocidal antibody titres - for epidemiological studies

Case Definition (WHO / IDSP)

DefinitionCriteria
Suspected casePatient ≥5 years with acute watery diarrhoea and severe dehydration OR death from acute watery diarrhoea, in a cholera-affected area
Confirmed caseSuspected case + V. cholerae O1 or O139 isolated from stool
Notifiable?YES - Cholera is a MANDATORY notifiable disease under IDSP; also under IHR 2005 - potential Public Health Emergency of International Concern (PHEIC); report to CMO within 24 hours

4. TREATMENT

General / Supportive Care - Rehydration is EVERYTHING ⭐

"The death from cholera is due to hypovolaemic shock; thus treatment first and foremost requires fluid resuscitation." - Harrison's
ORS - Why it works: Glucose-Na⁺ co-transport in the gut remains intact even when cholera toxin is active → oral rehydration possible
Rehydration Plans:
SeverityTreatmentVolume
None/Mild (Plan A)ORS at home50-100 mL after each loose stool
Moderate (Plan B)ORS in facilityAge/weight-based (e.g., ≥15 years: 2200-4000 mL over 4 hrs)
Severe (Plan C)IV Ringer's Lactate100 mL/kg in first 3 hours (adults); 6 hours (children <12 months); start RAPIDLY then slow
If Ringer's Lactate unavailable → Normal Saline (0.9% NaCl) Reassess every 15-30 minutes during IV resuscitation
Continue feeding after rehydration; breastfeeding must continue

Specific Treatment

ParameterDetails
AntibioticsShorten duration of diarrhoea and reduce fluid loss by ~50%; NOT a substitute for rehydration
Drug of choice (adults)Doxycycline 300 mg - single dose (most effective, cheapest)
Drug of choice (children)Azithromycin 20 mg/kg - single dose
Drug of choice (pregnant)Azithromycin 1g - single dose
AlternativesTetracycline 500 mg QDS x 3 days; Ciprofloxacin 1g single dose; Erythromycin
ResistanceTetracycline/doxycycline resistance reported from Bangladesh, India; check local antibiogram
Zinc supplementation20 mg/day x 14 days in children (adjunct)

Isolation & Notification

  • Isolation type: Enteric/contact precautions; strict stool/vomit disposal
  • Duration: Until 3 consecutive stool cultures are negative
  • Notification: Immediate (within 24 hours) to CMO; report to State Health Dept; IDSP war room; IHR 2005 reporting if international spread suspected

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
Immediate / AcuteHypovolaemic shock → Death (most dangerous; can occur within 4-12 hours of onset)
MetabolicHypokalaemia (muscle cramps, cardiac arrhythmia), Metabolic acidosis, Hyponatraemia
RenalAcute Kidney Injury / Acute Tubular Necrosis (from profound hypoperfusion) ⭐
CardiovascularCardiac arrhythmias (from hypokalaemia); circulatory collapse
PulmonaryAspiration pneumonia (from vomiting in obtunded patient)
ObstetricIntrauterine fetal death, premature labour in pregnant women
Treatment complicationsFluid overload (cerebral oedema in children if over-rapid rehydration); antibiotic resistance
"Cholera sicca"Paradoxical - death from shock before diarrhoea appears (fluid sequestered in gut) ⭐
⭐ Most dangerous complication: Hypovolaemic shock - can kill in hours With adequate rehydration: case fatality rate (CFR) <1%; without treatment: CFR 25-50%

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Safe water supply: chlorination (0.5 ppm residual chlorine), boiling, filtration
  • Proper sanitation: use of latrines; ODF campaigns (Swachh Bharat Mission)
  • Hand-washing with soap: especially before food and after defecation
  • Food hygiene: avoid raw/undercooked shellfish and seafood; cook food thoroughly
  • Proper disposal of faeces and vomitus
  • Avoid use of raw sewage as fertiliser

Primary Prevention - Specific Protection

Immunization:
VaccineTypeEfficacySchedule
Shanchol (OCV)Killed oral bivalent (O1 + O139)~65-85% for 2 years2 doses, 2 weeks apart (≥1 year of age) ⭐
OrcVax (mORCVAX)Killed oralSimilar2 doses
DukoralKilled oral + recombinant B subunit~85% short-term2 doses (travellers)
Old killed parenteral vaccineKilled parenteral (injectable)Only 50%; short durationNo longer recommended ⭐
Cholera vaccine is NOT included in India's UIP - used in outbreak/endemic settings and for travellers
Chemoprophylaxis: Doxycycline for household contacts in some protocols (not routinely recommended - may mask cases and create resistance)
Personal protection: Boil water; avoid raw foods; hand hygiene

Secondary Prevention

  • Active case finding - identify all cases in community rapidly
  • Surveillance under IDSP - any cluster of acute watery diarrhoea is an alert
  • Water quality monitoring - regular testing of water supply for coliforms
  • Contact tracing - screen and observe household contacts
  • Stool culture of contacts - identify asymptomatic carriers

Tertiary Prevention - Rehabilitation

  • Nutritional rehabilitation post-recovery
  • Fluid/electrolyte correction for residual deficits
  • Renal function monitoring post-AKI
  • Psychological support for affected communities

Control Measures During an Outbreak ⭐

  • Case isolation: Enteric precautions; dedicated cholera cots (holes cut for stool collection and measurement)
  • Contact tracing: All household contacts observed; prophylaxis if appropriate
  • Water safety: Emergency chlorination; ban on contaminated water source; boil-water advisory
  • Food safety: Identify and close contaminated food sources; screen food handlers
  • Disinfection: Concurrent (ongoing) with 1% bleach/sodium hypochlorite; terminal disinfection
  • Cholera Treatment Centre (CTC): Dedicated facility; Oral Rehydration Corners (ORC)
  • Epidemiological investigation: Identify source (point vs propagated), attack rate, epidemic curve
  • Mass vaccination (OCV): WHO recommends reactive vaccination in outbreaks alongside WASH measures
  • Notification: CMO → State → Centre → IHR 2005 (WHO)
  • Media management: Prevent panic while warning community

National Programs & WHO Goals

ProgramDetails
National Cholera Control ProgrammeIndia - surveillance, case management, OCV stockpile
Swachh Bharat MissionLaunched 2 Oct 2014; ODF India - major preventive tool ⭐
Jal Jeevan MissionSafe piped water to all rural households - key prevention
IDSPAll outbreaks and cases reported; War room surveillance
WHO Global Task Force on Cholera Control (GTFCC)"Ending Cholera: A Global Roadmap to 2030" - target 90% reduction in cholera deaths by 2030
Global OCV StockpileWHO/UNICEF/MSF maintain emergency oral cholera vaccine stockpile for outbreak response
IHR 2005Cholera - potential PHEIC; international notification mandatory

EXAM TIPS FOR CHOLERA

Always MentionKey Facts
Incubation periodFew hours to 5 days (usually 24-48 hrs)
Period of communicabilityThroughout symptomatic phase; El Tor - weeks in carriers
NotifiableYES - IHR 2005 + IDSP mandatory
Causative agentV. cholerae O1 (El Tor biotype) / O139
7th Pandemic began1961, Indonesia (El Tor biotype) ⭐
Pathognomonic signRice-water stools + washerwoman skin ⭐
Drug of choiceDoxycycline 300 mg single dose (adults) ⭐
Cornerstone of treatmentRehydration (ORS Plan A/B; Ringer's Lactate Plan C) ⭐
Gold standard diagnosisStool culture on TCBS agar ⭐
Hanging drop testDarting motility of vibrios
Most dangerous complicationHypovolaemic shock (CFR 25-50% untreated; <1% treated)
Blood group riskBlood group O = highest risk ⭐
Cholera toxin mechanism↑cAMP → ↑Cl⁻ secretion → rice-water stool ⭐
WHO 2030 goal90% reduction in cholera deaths

Ready for the next disease! Just name it.

Cjolera

I think you meant Cholera again! I already covered it in full detail just above. Here's a quick recap:

CHOLERA - Quick Summary

SectionKey Points
AgentVibrio cholerae O1 (El Tor biotype) / O139; curved Gram-negative bacillus
ReservoirAquatic environment + human gut; NO animal reservoir
TransmissionFaecal-oral; contaminated water (#1); incubation 24-48 hrs
Pathognomonic⭐ Rice-water stools + washerwoman skin; NO fever, NO blood
VirulenceCholera toxin → ↑cAMP → massive Cl⁻/water secretion
Diagnosis (Gold std)Stool culture on TCBS agar; hanging drop = darting motility
Treatment⭐ Rehydration FIRST (ORS/Ringer's Lactate) + Doxycycline 300 mg single dose
Most dangerousHypovolaemic shock (CFR 25-50% untreated; <1% with treatment)
VaccineShanchol (killed oral, 2 doses) - NOT in UIP
7th Pandemic1961, Indonesia (El Tor biotype); currently ongoing
WHO 2030 goal90% reduction in cholera deaths

Scroll up for the complete full proforma. Ready for the next disease - just name it! 😊

Typhoid

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent - I have rich data from Harrison's, Park's PSM textbook, and Tintinalli's. Here is your complete proforma:

TYPHOID FEVER (ENTERIC FEVER)

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM


1. EPIDEMIOLOGY

Agent Factors (Epidemiological Triad)

ParameterDetails
Causative agentSalmonella typhi (primary); S. paratyphi A, B, C (paratyphoid - milder disease)
TypeGram-negative bacillus, Family Enterobacteriaceae; facultative intracellular pathogen
AntigensO antigen (somatic - rises in disease), H antigen (flagellar - rises with vaccination), Vi antigen (virulence capsular antigen - present in 80% of chronic carriers) ⭐
Phage typesAt least 80 phage types - used for epidemiological tracing of outbreaks
Source of infectionFaeces and urine of cases/carriers (primary); contaminated water, food, fingers, flies (secondary)
ReservoirHuman only - strict anthroponosis (NO animal reservoir) ⭐
Infective materialFaeces (primary), urine
SurvivalSurvives in water 7 days; ice and ice cream >1 month; soil irrigated with sewage up to 70 days; multiplies rapidly in milk
Carrier stateTemporary (incubatory, convalescent) and Chronic (excrete >1 year, usually in gall bladder); 2-5% of cases become chronic carriers; "Typhoid Mary" - famous example ⭐
MDR strainsResistance to chloramphenicol + ampicillin + cotrimoxazole = MDR S. typhi; XDR (extensively drug resistant) strains also reported from Pakistan

Host Factors

ParameterDetails
Age groupAny age; highest incidence in 5-19 years; school-age and young adults ⭐
SexMore cases in males (greater exposure); but carrier rate higher in females
ImmunityCell-mediated immunity (CMI) is primary defence (intracellular organism); antibodies are secondary; natural infection does NOT always confer solid immunity
Susceptibility increased byAchlorhydria, H. pylori infection, PPIs, malnutrition, immunocompromise
Chronic carrier riskHigher in women, infants, those with biliary abnormalities or Schistosoma haematobium bladder infection

Environmental Factors

  • Season/Climate: Present year-round; peak incidence in July-September (rainy season, increased fly population, flooding) ⭐
  • Geography: Endemic in Indian subcontinent (India, Pakistan, Bangladesh, Nepal), South-East Asia, Africa, Latin America; India: 2.30 million cases/year (IDSP 2018); max cases from Uttar Pradesh
  • Socioeconomic: Unsafe water, open defecation, poor food hygiene, use of sewage-irrigated vegetables, low literacy, overcrowding

Transmission

ParameterDetails
ModeFaecal-oral (primary) and urine-oral
Routes (5 Fs)Fluids (contaminated water/ice), Food (especially milk, shellfish, vegetables), Fingers (hand contamination), Flies, Fomites
No respiratory transmissionS. typhi NOT excreted in sputum; NOT spread by droplet
Portal of entryGI tract (oral ingestion)
Incubation periodUsually 10-14 days (range 3-21 days depending on inoculum size) ⭐
Period of communicabilityThroughout clinical illness and carrier state; convalescent carriers shed for 6-8 weeks; chronic carriers shed for years (intermittently or continuously)

Descriptive Epidemiology

  • Global burden: 11-20 million cases/year; 128,000-161,000 deaths/year (WHO); predominantly children of school age; highest incidence on Indian subcontinent (>1000 cases/100,000 children in some areas)
  • Indian scenario: Endemic; 2.30 million cases and 399 deaths in 2018 (IDSP); notifiable disease; Typhoid Conjugate Vaccine (TCV) introduced in UIP 2021-22
  • Epidemic pattern: Endemic with epidemic potential; point-source outbreaks (contaminated water/food supply); sporadic cases from carriers; "Typhoid is an index of general sanitation of a country" (Park) ⭐

2. CLINICAL FEATURES

Stages of Disease - Classic 4-Week Pattern ⭐

WeekStageFeatures
Week 1Prodromal / IncubationGradual onset fever (step-ladder pattern), headache, malaise, anorexia, dry cough, coated tongue, constipation (children may have diarrhoea)
Week 2Fastigium (Stage of invasion)Continuous high fever (39-40°C), relative bradycardia, Rose spots appear, splenomegaly, hepatomegaly, toxic appearance
Week 3Stage of maximum illnessFever sustained; complications appear (perforation, bleeding); "muttering delirium / coma vigil"; patient picks at bedclothes
Week 4Defervescence / ConvalescenceGradual resolution; fever decreases; recovery begins; relapse possible

Cardinal / Pathognomonic Features ⭐

  • Step-ladder pattern of fever - rises by 1°F each day, progressively to 103-104°F ⭐
  • Relative bradycardia (Faget's sign) - pulse rate lower than expected for the degree of fever ⭐
  • Rose spots (Roseola typhosa) - faint salmon-colored, blanching maculopapular rash on trunk/chest; appear at end of first week in ~30% of cases ⭐
  • Coated tongue ("strawberry tongue" appearance at tip and edges) - present in 51-56%
  • Splenomegaly - soft tender spleen in 2nd week
  • Hepatomegaly - common
  • Constipation (adults) or Diarrhoea (children/paratyphoid)
  • "Pea soup" stools - characteristic diarrhoea when it occurs
  • Muttering delirium / Coma vigil - neuropsychiatric symptom in severe disease ⭐

Clinical Types / Grades / Severity

TypeFeatures
Typical typhoidClassic 4-week illness with all features above
Mild/ambulatory typhoidSubclinical or mild febrile illness; common in endemic areas with partial immunity
Typhoid of infancyVomiting, diarrhoea, convulsions; high mortality
Complicated typhoidWith intestinal perforation, haemorrhage, or neurological involvement
ParatyphoidCaused by S. paratyphi A/B/C; shorter, milder course; similar clinical picture
Carrier stateChronic asymptomatic carrier - most in gall bladder; 2-5% of cases

3. DIAGNOSIS

Lab Investigations

InvestigationDetailsTiming
Blood culture40-60% sensitivity; best in Week 1 (bacteraemia peaks)Week 1-2 ⭐
Bone marrow cultureGOLD STANDARD - ~80% sensitivity; not reduced by prior antibiotics (up to 5 days)Any time
Stool culturePositive in Week 3-4 (when organism shed in bile back into gut)Week 3-4
Urine culturePositive in Week 3-4Week 3-4
String (duodenal) testCaptures intestinal secretions; useful for carriers; combined with above gives >90% yieldAny time
Widal testAgglutination test - O titre ≥1:160 (active disease); H titre ≥1:160 (past infection/vaccination); NOT reliable as standalone - many false positives/negatives ⭐Week 2 onwards
Typhidot / TUBEXRapid IgM/IgG detection; sensitivity ~70-80%, specificity ~80-90%; useful point-of-careWeek 1-2
CBCLeucopenia + neutropenia (15-25% of cases) ⭐; raised ESR; mild anaemia; thrombocytopenia in severe disease
LFTModerately raised transaminases; mild jaundice in hepatitis form

Widal Test Interpretation ⭐

TitreInterpretation
O antigen ≥1:160Active infection (O titre is diagnostic)
H antigen ≥1:160Past infection OR vaccination (H titre persists)
Rising titre (4-fold)Confirms active infection
Vi antigen positiveCarrier state (80% of chronic carriers)

Case Definition (WHO / IDSP)

DefinitionCriteria
Suspected caseFever ≥38°C for ≥3 days + compatible clinical features (headache, abdominal pain, rose spots)
Probable caseSuspected case + positive Widal/Typhidot test
Confirmed case⭐ S. typhi or S. paratyphi isolated from blood/bone marrow/stool/urine culture
Notifiable?YES - notifiable under IDSP; report to CMO

4. TREATMENT

General / Supportive Care

  • Bed rest throughout febrile period
  • High-calorie, soft/liquid diet - easily digestible; avoid high-roughage foods (risk of perforation)
  • Adequate hydration - oral or IV
  • Antipyretics (paracetamol preferred - avoid NSAIDs due to bleeding risk)
  • Treat complications promptly
  • Steroids: Dexamethasone 3 mg/kg IV loading dose then 1 mg/kg every 6 hours x 8 doses - ONLY in severe disease with altered consciousness/shock ⭐

Specific Treatment ⭐

Current Antibiotic Recommendations (Harrison's 2025):
IndicationDrugDoseDuration
Empirical (unknown susceptibility)Ceftriaxone (IV) OR Azithromycin (oral)Ceftriaxone 2g/day IV; Azithromycin 1g day 1 then 500 mg OD7-14 days
Fully sensitive S. typhiChloramphenicol OR Ampicillin OR CotrimoxazoleChloramphenicol 25 mg/kg/day14 days
MDR S. typhi (resistant to Chlor/Amp/Cotrim)Ceftriaxone OR AzithromycinAs above7-10 days
XDR S. typhi (also resistant to FQ + 3rd gen cephalosporins)Azithromycin1g then 500 mg OD7 days
Decreased susceptibility to Ciprofloxacin (DSC)Avoid fluoroquinolones; use Azithromycin or Ceftriaxone
Uncomplicated (where FQ still sensitive)Ciprofloxacin 500 mg BD7-10 days
Note for India/PSM exams: Traditional teaching = Chloramphenicol was the original DOC; now Ceftriaxone or Azithromycin are preferred due to widespread MDR. Fluoroquinolones NO LONGER first-line on Indian subcontinent due to DSC strains.
Carrier treatment:
  • Ampicillin/Amoxicillin 4-6g/day + Probenecid 2g/day x 6 weeks (concentrated in bile) - 70% clearance
  • Cholecystectomy + antibiotics for carriers with cholelithiasis ⭐

Isolation & Notification

  • Isolation type: Enteric precautions (contact precautions for faeces/urine)
  • Duration: Until 3 consecutive negative stool AND urine cultures on 3 separate days ⭐
  • Notification: Mandatory to CMO under IDSP within 24 hours; all outbreaks to State + Centre

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
GI - Most commonIntestinal perforation (1%) - Week 3-4; ileal Peyer's patches ulcerate; acute abdomen; requires emergency surgery + broad-spectrum antibiotics ⭐
GI - Second most commonIntestinal haemorrhage (6%) - Week 3-4; melaena or fresh blood PR; transfusion may be needed
HepaticTyphoid hepatitis, hepatomegaly, jaundice
SplenicSplenic rupture (rare but dramatic)
Neurological (2-40%)Typhoid encephalopathy / Muttering delirium / Coma vigil ⭐; meningitis; Guillain-Barré syndrome; neuritis
CardiovascularMyocarditis; circulatory collapse; DIC
HaematologicalThrombocytopenia; DIC; haemolytic anaemia
RespiratoryPneumonia; rarely pleuritis
RenalGlomerulonephritis; HUS (rare)
RelapseUp to 10% of cases; occurs 2-3 weeks after fever resolution; same strain ⭐
Carrier state2-5% become chronic carriers (gall bladder); associated with increased risk of gallbladder cancer
Complications of treatmentHerxheimer-like reaction; antibiotic resistance
⭐ Most dangerous acute complication: Intestinal perforation (mortality 10-32%) CFR: 2.5% overall; 10-30% if untreated; <1% with prompt treatment

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Safe water supply: chlorination, boiling, filtration
  • Proper sanitation: use of latrines; ODF campaigns (Swachh Bharat Mission)
  • Hand-washing with soap before eating and after defecation
  • Food hygiene: avoid raw milk, unwashed vegetables, shellfish; cook food thoroughly
  • Fly control: proper garbage disposal, insecticides
  • Avoid street food in endemic areas
  • "Typhoid is a index of sanitation" - improve general living standards

Primary Prevention - Specific Protection

Immunization - Three Vaccines Available:
VaccineTypeEfficacyRouteScheduleDuration
TAB vaccine (old, killed parenteral)Killed whole-cell~70-90% short-termSC injection2 doses 4 weeks apart + booster every 3 years3 years; NOW largely REPLACED
Vi polysaccharide vaccine (Typherix/Typhim Vi)Purified Vi capsular polysaccharide~60-80%IM/SC; single doseSingle dose; booster every 3 years3 years; for adults + children >2 yrs
⭐ Typhoid Conjugate Vaccine (TCV - Typbar-TCV)Vi polysaccharide conjugated to tetanus toxoid~80-85%IM; single doseIndia UIP: Single dose at 9-12 months (introduced 2021-22) ⭐Long-lasting; T-cell dependent immunity
Ty21a (Vivotif)Live attenuated oral~67-80%Oral; 3-4 capsules alternate daysNot in India UIP; used in travellers5 years
Key exam fact: TCV (Typhoid Conjugate Vaccine) introduced into India's UIP as a single dose at 9-12 months - conjugation allows use in infants <2 years (Vi polysaccharide alone is T-independent - ineffective <2 yrs)
Chemoprophylaxis: Not routinely recommended

Secondary Prevention

  • Early diagnosis of cases - blood culture in all unexplained fever >3 days
  • Carrier detection: Vi antibody testing + stool culture for food handlers, water supply workers; duodenal drainage for biliary carrier confirmation
  • Carrier management: Treatment with amoxicillin/probenecid; restrict from food handling
  • Active case-finding during outbreaks
  • IDSP surveillance - alert on clusters of febrile illness
  • Widal screening in outbreak settings (with limitations)

Tertiary Prevention - Rehabilitation

  • Nutritional rehabilitation post-illness (recovery takes weeks to months)
  • Monitoring for relapse (2-3 weeks post-defervescence)
  • Follow-up stool and urine cultures at 3-4 months and 12 months to detect carrier state
  • Surgical follow-up for intestinal perforation cases
  • Cholecystectomy consideration for chronic gallbladder carriers

Control Measures During an Outbreak

  • Case isolation: Enteric precautions until 3 negative stool/urine cultures
  • Contact tracing: Stool cultures of all household contacts; identify carrier
  • Source identification: Water/food/carrier - epidemic curve analysis
  • Water supply: Emergency chlorination; test water samples; boil-water advisory
  • Food handlers: Screen all; remove positive cases from food handling duties
  • Disinfection: Faeces/urine received in closed containers + 5% cresol for 2 hours ⭐; soiled linen in 2% chlorine + steam sterilization
  • Fly control: Insecticides, proper waste disposal during outbreak
  • Notification: CMO → State → Centre under IDSP
  • Outbreak vaccination: TCV/Vi vaccine to contacts and community

National Programs & WHO Goals

ProgramDetails
Typhoid Conjugate Vaccine in UIPSingle dose at 9-12 months; India phased rollout 2021-22 ⭐
Swachh Bharat MissionODF India; launched 2 Oct 2014; most effective typhoid prevention at population level ⭐
Jal Jeevan MissionSafe piped water to all rural households
IDSPSurveillance; typhoid is notifiable
WHO targetPromote TCV globally; integrate into childhood immunization schedules in endemic countries

EXAM TIPS FOR TYPHOID FEVER

Always MentionKey Facts
Incubation period10-14 days (range 3-21 days) ⭐
Period of communicabilityThroughout illness + carrier state
NotifiableYES - under IDSP
ReservoirHuman only (no animal reservoir) ⭐
Hallmark clinical featuresStep-ladder fever + relative bradycardia + rose spots ⭐
Week of complicationsWeek 3-4 (perforation, bleeding) ⭐
Gold standard diagnosisBone marrow culture (~80% sensitivity) ⭐
Best practical diagnosisBlood culture in Week 1
Widal interpretationO titre ≥1:160 = active disease; Vi = carrier
Most dangerous complicationIntestinal perforation ⭐
Drug of choiceCeftriaxone or Azithromycin (MDR era) ⭐
Isolation durationUntil 3 negative stool + urine cultures ⭐
Carrier female example"Typhoid Mary" ⭐
Vaccine in India UIPTCV (Typhoid Conjugate Vaccine) - 9-12 months ⭐
National programSwachh Bharat Mission + TCV in UIP
Carrier percentage2-5% of cases become chronic carriers
Carrier Vi antigenPositive in 80% of chronic carriers

Ready for the next disease! Just name it. 😊

Food poisoning

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Park's PSM textbook and Medical Microbiology. Here is your full proforma:

FOOD POISONING

Communicable Disease Epidemiology Proforma | 3rd Year BSc / PSM

Note for exam: Food poisoning is a syndrome caused by multiple agents. In PSM exams, questions usually ask you to compare types in a table or describe the most important types (Staphylococcal, Salmonella, Botulism, Cl. perfringens, B. cereus). Always define it first, then cover each type systematically.

1. EPIDEMIOLOGY

Definition ⭐

Food poisoning is an acute gastroenteritis caused by ingestion of food or drink contaminated with:
  • Living bacteria (infective type)
  • Their preformed toxins (toxic/intoxication type)
  • Inorganic chemicals, or poisons from plants/animals
Diagnostic Triad (Park's):
  1. History of ingestion of a common food by a group
  2. Attack of many persons at the same time
  3. Similarity of signs and symptoms in the majority

Classification of Food Poisoning

A. Non-Bacterial:
  • Chemicals: arsenic, lead, mercury, cadmium, pesticides, fertilisers
  • Plant toxins: mushrooms, solanine (green potatoes)
  • Animal toxins: puffer fish (tetrodotoxin), shellfish toxins
B. Bacterial (Most Important for Exams):
TypeAgentMechanism
Toxic (Intoxication)Staph. aureus, Cl. botulinum, B. cereus (emetic)Preformed toxin in food ingested (intradietetic toxin) - NO bacterial multiplication in gut needed
InfectiveSalmonella spp., ETEC, VibrioLiving bacteria ingested → multiply in gut → toxin produced in vivo
MixedCl. perfringens, B. cereus (diarrhoeal)Bacteria ingested → sporulate/multiply → produce toxin in gut

Agent Factors - Comparison Table ⭐

FeatureSalmonellaStaph. aureusCl. botulinumCl. perfringensB. cereus
TypeInfectiveToxic (preformed)Toxic (preformed)MixedMixed (2 types)
AgentS. typhimurium, S. enteritidisCoagulase +ve Staph. aureus (enterotoxin)Exotoxin types A, B, EAlpha toxinEmetic toxin / Diarrhoeal enterotoxin
Incubation12-24 hrs1-8 hrs (shortest!)18-36 hrs6-24 hrs (peak 10-14 hrs)Emetic: 1-5 hrs; Diarrhoeal: 8-16 hrs
Common foodMeat, eggs, poultry, milkCustards, salads, milk, pastries, hamHome-canned veg, smoked fish, home-made cheeseMeat dishes, poultry (cooked and reheated)Fried/boiled rice (emetic); meat/vegetables (diarrhoeal)
FeverYES (chills, fever)NO ⭐NONO/minimalNO
VomitingYESYES (prominent)MinimalRareYES (emetic type)
DiarrhoeaYES (watery)YESNO/minimalYESYES (diarrhoeal type)
Key featureFever + gastroenteritisVomiting prominent, NO fever, short IPNeurological symptoms ⭐Diarrhoea + cramps, NO vomiting"Fried rice illness" (emetic type)
Duration2-3 days<24 hrs4-8 days (fatal)<24 hrs (1 day)<24 hrs

Host Factors

ParameterDetails
Age groupAll ages; elderly, infants, immunocompromised at highest risk of severity
SexNo significant difference
Risk factorsImproper food storage, mass/community feeding, banquets/weddings, food handler as carrier, immunocompromise
SusceptibilityUniversal; gastric acidity is a partial protective barrier

Environmental Factors

  • Season/Climate: Summer/hot months - bacterial growth favored by heat; inadequate refrigeration
  • Geography: Worldwide; higher burden in developing countries with poor food safety infrastructure; India - mass feeding events (weddings, religious gatherings), school mid-day meals
  • Socioeconomic: Community feeding, prepared foods left at room temperature, poor kitchen hygiene, improper cold chain, flies, lack of handwashing

Transmission

ParameterDetails
ModeIngestion of contaminated food (NOT person-to-person in most types)
VehicleSpecific foods for each type (see table above)
Key characteristicExplosive point-source outbreak - many people affected simultaneously after a common meal ⭐
Portal of entryGI tract
Incubation periodVaries by agent (1-8 hrs = Staph; 18-36 hrs = Botulism; 12-24 hrs = Salmonella)
NOT communicableFood poisoning is NOT communicable person-to-person (except Salmonella which can spread secondarily)

Descriptive Epidemiology

  • Global burden: Food-borne illness affects ~600 million people/year globally (WHO); ~420,000 deaths/year; significant economic burden
  • Indian scenario: Major public health problem; school mid-day meal outbreaks (Salmonella/Staph); notifiable under IDSP; mass gathering outbreaks common; FSSAI (Food Safety and Standards Authority of India) regulates food safety
  • Epidemic pattern: Explosive point-source outbreak - all cases occur within one incubation period; epidemic curve shows narrow, sharply peaked histogram ⭐

2. CLINICAL FEATURES

Stages of Disease

StageFeatures
Incubation periodVery short (1-8 hrs for toxin types) to 12-36 hrs for infective types
ProdromalUsually absent - sudden onset
Acute phaseNausea, vomiting, diarrhoea, abdominal cramps - vary by agent
ConvalescenceRapid recovery in most types (except botulism); usually self-limiting

Cardinal / Pathognomonic Features by Type ⭐

1. Salmonella Food Poisoning (Infective type)
  • Sudden onset chills + fever + nausea + vomiting + profuse watery diarrhoea
  • Incubation 12-24 hours
  • Lasts 2-3 days; mortality ~1%
  • Convalescent carrier state possible
2. Staphylococcal Food Poisoning (Toxic type) ⭐
  • Shortest incubation: 1-8 hours (preformed toxin)
  • Sudden onset severe vomiting (most prominent) + abdominal cramps + watery diarrhoea
  • NO FEVER (heat-stable, preformed toxin - not an infection) ⭐
  • Recovery within 24 hours
  • Food does NOT taste or appear spoiled
  • Source: food handler with skin infection OR asymptomatic nasal carrier
3. Botulism (Toxic type) ⭐ - MOST SERIOUS
  • Incubation 18-36 hours
  • NEUROLOGICAL symptoms predominate - NOT GI ⭐
  • Diplopia, dysphagia, dysarthria, ptosis, blurring of vision, muscle weakness, quadriplegia
  • Descending flaccid paralysis (cranial nerves first, then downward)
  • NO fever; consciousness retained
  • GI symptoms minimal
  • Death from respiratory failure in 4-8 days ⭐
  • Kills ~two-thirds of victims if untreated
  • Infant botulism - in vivo toxin production (ingestion of spores, e.g., honey)
4. Cl. perfringens Food Poisoning (Mixed type)
  • Incubation 6-24 hours (peak 10-14 hrs)
  • Diarrhoea + abdominal cramps; NO vomiting, NO fever
  • Short duration (<24 hours); NO deaths reported
  • Caused by reheated meat/poultry (spores survive cooking, germinate during slow cooling)
5. B. cereus Food Poisoning (Two types) ⭐
  • Emetic type ("Fried rice illness"): IP 1-5 hrs; vomiting prominent; similar to Staph; caused by eating cooked rice left at room temperature
  • Diarrhoeal type: IP 8-16 hrs; diarrhoea + cramps; similar to Cl. perfringens

Clinical Types / Grades

GradeFeatures
MildSelf-limiting GI symptoms; no dehydration
ModerateSignificant vomiting/diarrhoea; some dehydration
SevereSevere dehydration, electrolyte imbalance, shock (Salmonella); respiratory paralysis (Botulism)

3. DIAGNOSIS

Lab Investigations

InvestigationDetails
Clinical diagnosisExplosive outbreak + common food + similar symptoms + short incubation period
Stool examinationMicroscopy (pus cells, RBCs); culture (Salmonella)
Food cultureCulture of implicated food - most important in outbreak investigation ⭐
Vomitus cultureStaph. aureus (coagulase-positive)
Food toxin testingELISA for staphylococcal enterotoxin; mouse bioassay for botulinum toxin ⭐
Blood cultureIn Salmonella bacteraemia
Stool for Cl. perfringens>10⁵ organisms/g in implicated food
Serum botulinum toxinMouse inoculation test - gold standard for botulism
CBCLeucocytosis in infective type (Salmonella); normal in toxic type (Staph)
ElectrolytesFor dehydration assessment

Case Definition (WHO / IDSP)

DefinitionCriteria
Suspected outbreak≥2 persons with similar illness after consuming a common food
Confirmed caseIsolation of pathogen from food/stool/blood OR detection of toxin
Botulism suspectedDescending paralysis after eating home-preserved food
Notifiable?YES - all food poisoning outbreaks are notifiable under IDSP; report to CMO and Food Safety Officer (FSSAI) within 24 hours ⭐

4. TREATMENT

General / Supportive Care

  • Majority are self-limiting - supportive care is the cornerstone
  • Rehydration: ORS (Plan A/B) for mild-moderate dehydration; IV Ringer's Lactate for severe dehydration
  • Antipyretics (for Salmonella with fever)
  • Antiemetics (metoclopramide/ondansetron) for severe vomiting
  • Rest and NPO initially, then gradual oral refeeding
  • Monitor: Vitals, fluid balance, electrolytes

Specific Treatment

AgentSpecific TreatmentNotes
SalmonellaUsually supportive; Ciprofloxacin or Azithromycin if severe/bacteraemicAntibiotics NOT needed for mild cases (may prolong carrier state)
Staph. aureusSupportive only - antibiotics NOT indicated ⭐Preformed toxin - antibiotics useless; rapid recovery
BotulismTrivalent botulinum antitoxin (A, B, E) 50,000-100,000 units IV + respiratory support (ICU/ventilator)Antitoxin only works BEFORE toxin binds to nerve; respiratory support may be needed for weeks
Cl. perfringensSupportive onlySelf-limiting; no antibiotics needed
B. cereusSupportive onlySelf-limiting; no antibiotics needed
Key exam point: Antibiotics are generally NOT indicated in food poisoning (toxic types). Exception: severe Salmonella with bacteraemia or risk of systemic spread.

Isolation & Notification

  • Isolation type: Enteric precautions (contact precautions for stool)
  • Duration: Until symptoms resolve
  • Notification: All outbreaks notified to CMO under IDSP within 24 hours; food safety violation reported to FSSAI

5. COMPLICATIONS ⭐

System-wise Complications

TypeComplication
Immediate / AcuteRespiratory failure in Botulism (MOST DANGEROUS) - requires ventilator
Fluid/ElectrolyteSevere dehydration, hypovolaemic shock, hyponatraemia, hypokalaemia (especially Salmonella)
RenalAcute kidney injury from dehydration
NeurologicalDescending paralysis, cranial nerve palsies, diplopia (Botulism) ⭐
GIIntestinal perforation/bleeding (rare, in Salmonella); toxic megacolon (rare)
HaematologicalHUS (Haemolytic Uraemic Syndrome) from EHEC (E. coli O157:H7) ⭐
Long-termPost-infectious IBS; Reactive arthritis (after Salmonella); chronic carrier state (Salmonella)
MortalityBotulism: 2/3 die if untreated ⭐; Salmonella: ~1% CFR
⭐ Most dangerous form: Botulism - respiratory failure; kills 2/3 untreated ⭐ Most common form: Staphylococcal food poisoning (equally common as Salmonella)

6. PREVENTION AND CONTROL (Most Scoring Section)

Primary Prevention - Health Promotion

  • Food safety education for food handlers, cooks, caterers ⭐
  • Proper hand-washing before food preparation and after toilet
  • Personal hygiene: food handlers with skin infections/boils should NOT handle food (Staph)
  • Proper cooking: cook food to internal temperature ≥70°C (kills vegetative bacteria)
  • Safe storage: refrigerate at <5°C; hot food kept at >60°C (danger zone: 5-60°C = bacterial growth zone)
  • Avoid leaving cooked food at room temperature for >2 hours ⭐
  • Avoid reheating rice/meat dishes (Cl. perfringens, B. cereus)
  • Proper hygiene in community feeding/mass catering

Primary Prevention - Specific Protection

No routine vaccines available for most food poisoning types
MeasureDetails
Botulinum toxoidAvailable for laboratory workers and high-risk groups; NOT in general use
Cold chain maintenanceRefrigeration of perishable foods; cold chain for dairy/meat products
Food irradiationWHO-approved method to kill pathogens in food
PasteurisationKills Salmonella, Staph in milk and dairy products
HACCPHazard Analysis Critical Control Points - food industry standard ⭐
Food handler screeningStool cultures of food handlers in high-risk settings; nasal swabs for Staph carriage
Antitoxin prophylaxisBotulinum antitoxin given to all persons who ate the implicated food in a botulism outbreak ⭐

Secondary Prevention

  • Rapid outbreak detection through IDSP alert system
  • Active case finding - identify all who ate the common meal
  • Food sample collection and testing within 48 hours of outbreak ⭐
  • Withdrawal and destruction of implicated food
  • Epidemiological investigation: attack rate by food items (cohort study); identify implicated food
  • Food handler investigation - culture stool/nasal swabs
  • Surveillance under IDSP and FSSAI

Tertiary Prevention - Rehabilitation

  • Nutritional rehabilitation after illness
  • Renal support for AKI
  • Long-term respiratory rehabilitation and physiotherapy for botulism survivors
  • Neurological rehabilitation for botulism sequelae

Control Measures During an Outbreak ⭐

  • Immediate removal of suspected food from service; seal and refrigerate for testing
  • Case isolation: Enteric precautions; hospital admission for severe/botulism cases
  • Contact tracing: Identify all persons who ate the implicated food; observe for symptoms
  • Antitoxin distribution: In botulism outbreak - antitoxin to all who ate implicated food
  • Disinfection: Kitchen surfaces, utensils, food preparation area
  • Epidemiological investigation:
    • Line list of all cases
    • Attack rate by food item (cohort study at the implicated event)
    • Spot map if mass gathering
    • Identify critical control point failure (improper storage? infected food handler?)
  • Notification: CMO (within 24 hrs) → IDSP war room → FSSAI
  • Health education: Community + media communication to prevent panic and recurrence

National Programs & WHO Goals

ProgramDetails
FSSAI (Food Safety and Standards Authority of India)Established under Food Safety and Standards Act, 2006 ⭐; regulates food safety, licensing, standards; key body for food poisoning prevention
IDSPAll food poisoning outbreaks notifiable; P-form + L-form surveillance
SWACHH BHARAT MISSIONImproved sanitation reduces food contamination
WHO "Five Keys to Safer Food"1. Keep clean; 2. Separate raw and cooked; 3. Cook thoroughly; 4. Keep food at safe temperatures; 5. Use safe water and raw materials
WHO Global Foodborne Disease Burden600 million cases/year; 420,000 deaths; SDG 2 (Zero Hunger) and SDG 3 (Good Health) relevant

EXAM TIPS FOR FOOD POISONING

Always MentionKey Facts
Shortest incubationStaph. aureus: 1-8 hours ⭐
Longest incubationBotulism: 18-36 hours
Most seriousBotulism (kills 2/3 untreated) ⭐
Most commonStaph. aureus and Salmonella (equally common)
NO feverStaph. aureus, Botulism, Cl. perfringens ⭐
NO vomitingCl. perfringens ("diarrhoea only") ⭐
Neurological symptomsBotulism only ⭐
"Fried rice illness"B. cereus (emetic type) ⭐
Treatment for BotulismTrivalent antitoxin + ventilator ⭐
Antibiotics NOT indicatedStaph, Cl. perfringens, B. cereus, mild Salmonella ⭐
Gold standard for botulismMouse bioassay for toxin
NotifiableYES - all outbreaks to CMO + FSSAI
Key regulatory bodyFSSAI (Food Safety and Standards Act, 2006)
WHO Five KeysKeep clean; Separate raw/cooked; Cook thoroughly; Safe temperatures; Safe water
Epidemic curve patternExplosive point-source; narrow single peak ⭐

Ready for the next disease! Just name it. 😊
This is a shared conversation. Sign in to Orris to start your own chat.